RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published today in the American Society of Hematology journal Blood. Volasertib has not been approved by the FDA; its safety and efficacy have not been established.
The study's primary endpoint showed the objective response rate (complete remission or complete remission with incomplete blood count recovery) was more than doubled for patients receiving volasertib and LDAC versus LDAC alone (31% versus 13.3%, p=0.052). The secondary endpoints of the study were overall survival, event-free survival, relapse-free survival and safety. The trial showed patients treated with volasertib combined with LDAC had a median overall survival of 8 months versus 5.2 months in patients treated with LDAC (p=0.047). Median event-free survival was prolonged in patients receiving volasertib and LDAC versus LDAC (5.6 months versus 2.3 months; p=0.021). Relapse-free survival for volasertib and LDAC versus LDAC was 18.5 months versus 10 months.
"Despite being a rare disease, AML is one of the most common leukemias in adults and predominantly affects older people. The established approach to treat younger AML patients is an intensive chemotherapy regimen, called intensive induction therapy. However, older patients often cannot tolerate these chemotherapy doses, and have very limited treatment options," commented Prof. Hartmut Dohner from the Department of Internal Medicine III of the University Hospital Ulm and principal investigator of the Phase II trial. "These clinical trial results that evaluated volasertib in combination with a lower intensity chemotherapy are important and have informed future research for this rare disease, where new treatment options are greatly needed."
There was an increase in non-hematologic adverse events (AEs) with volasertib and LDAC versus LDAC. The most common AEs with volasertib and LDAC versus LDAC, included febrile neutropenia grade 3 (38% vs. 7%), infections grade 3 (38% vs. 7%) and gastrointestinal AEs grade 3 (21% vs. 7%).
"We are pleased to see the Phase II results, including the new overall survival findings, of volasertib as published in ASH's current issue of Blood," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "We are continuing to research volasertib's potential in this rare disease in the ongoing Phase III study initiated last year and look forward to sharing the results with the broader AML community."
About the Volasertib Phase II Study
The open-label Phase II study enrolled 87 adult patients (median age 75 years) with AML not considered suitable for intensive induction therapy. Patients were randomly assigned to receive either volasertib in combination with LDAC (n=42) or LDAC (n=45). Patients were randomized in a 1:1 ratio to receive the combination of LDAC plus volasertib 350 mg intravenously over one hour on days 1 and 15 versus LDAC 20 mg twice daily subcutaneously on days 1-10 alone. Cycles were scheduled every four weeks until progression, relapse, intolerance, or patient/investigator requested discontinuation.
About Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive and devastating blood cancer mainly affecting people over age 60. It is one of the most common types of acute leukemia in adults, accounting for approximately one third of all adult leukemias in the Western world and with one of the lowest survival rates of all leukemias. In AML, prognosis worsens with increasing age, with a median survival of less than a year following diagnosis. The current standard of care for younger AML patients is intensive chemotherapy. However, 40% of AML patients cannot tolerate this treatment due to their age and comorbidities and the debilitating side effects. Especially for those older patients there is a medical need to research new treatment options.
Volasertib is an investigational compound that inhibits enzymes called Polo-like kinase (Plk). Plk1, the best understood of the five known Plks, has an important role in cell division (mitosis). This inhibition can result in prolonged cell cycle arrest, ultimately leading to cell death (apoptosis).
Volasertib is currently being evaluated in clinical trials for various solid tumors and hematological cancers. Boehringer Ingelheim is one of the first companies to advance Plk inhibitors into clinical development. Volasertib was granted Breakthrough Therapy Designation by the FDA in 2013 and Orphan Drug Designation by the FDA and the European Commission in 2014.
About the Volasertib Clinical Trial Program
Initiated in January 2013, POLO-AML-2 (clinical trial identifier: NCT01721876) is an ongoing global Phase III clinical trial designed to assess the efficacy and safety of volasertib in combination with LDAC, compared with placebo in combination with LDAC, in patients aged 65 years and older with previously untreated AML, ineligible for intensive remission induction therapy. The trial is currently enrolling eligible patients.
About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.
For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110.
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
For more information, please visit http://www.us.boehringer-ingelheim.com
Boehringer Ingelheim Pharmaceuticals, Inc.
Name: Paul Wynn
SOURCE Boehringer Ingelheim